Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against Pseudomonas aeruginosa by Inhibiting Drug Efflux
Open Access
- 26 August 2024
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 13 (9) , 810
Abstract
Pseudomonas aeruginosa is a multidrug-resistant Gram-negative pathogen and one of the leading causes of ventilator-associated pneumonia and infections in patients with chronic obstructive pulmonary disease and cystic fibrosis. Murepavadin is a peptidomimetic that specifically targets outer-membrane lipopolysaccharide transport protein LptD of P. aeruginosa. In this study, we find that murepavadin enhances the bactericidal efficacy of ciprofloxacin. We further demonstrate that murepavadin increases intracellular accumulation of ciprofloxacin by suppressing drug efflux. In addition, the murepavadin–ciprofloxacin combination exhibits a synergistic bactericidal effect in an acute murine pneumonia model. In conclusion, our results identify an effective drug combination for the treatment of P. aeruginosa infections.Keywords
Funding Information
- National Key Research and Development Program of China (2021YFE0101700, 32170177, 32170199, 22JCZDJC0041)
- National Science Foundation of China (2021YFE0101700, 32170177, 32170199, 22JCZDJC0041)
- Nankai University Tianjin Applied and Fundamental Research Project (2021YFE0101700, 32170177, 32170199, 22JCZDJC0041)
This publication has 58 references indexed in Scilit:
- Overview of Antibiotic-Induced NephrotoxicityKidney International Reports, 2023
- Counteracting antibiotic resistance enzymes and efflux pumpsCurrent Opinion in Microbiology, 2023
- Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatmentInfectious Medicine, 2023
- The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An UpdateDrugs, 2021
- In‐vitro evaluation of a ciprofloxacin and azithromycin sinus stent for Pseudomonas aeruginosa biofilmsInternational Forum of Allergy & Rhinology, 2019
- Nephrotoxicity of Ciprofloxacin: Five Cases and a Review of the LiteratureDrug Safety - Case Reports, 2018
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trialThe Lancet Infectious Diseases, 2018
- The small molecule IITR08027 restores the antibacterial activity of fluoroquinolones against multidrug-resistant Acinetobacter baumannii by efflux inhibitionInternational Journal of Antimicrobial Agents, 2017
- Combination therapies for combating antimicrobial resistanceCurrent Opinion in Microbiology, 2011
- Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an updateCurrent Opinion in Microbiology, 2009